

Seasonal influenza vaccination programme country profile: Czech Republic

2012–13 Season

Background information

Influenza immunisation policy and general facts about the Czech Republic	
Volume indices of GDP per capita in 2011 and 2013 (EU-28=100) Source: Eurostat ^a	83 and 82 respectively
Health costs as % of GDP 2011 Source: Eurostat ^b	7.8%
Total population of the country, 2011 Source: Eurostat ^c	10 436 560
Population ≥65, 2011 Source: Eurostat ^c	1 644 836 (15.8% from the total population)
Population with chronic medical conditions <65 years, 2006 Source: ECDC (based on methodology by Fleming and Elliot, 2006) ^d	853 000 (8.2% from the total population)
Number of live births in 2011 ^e	108 673 (1% from the total population)
National seasonal influenza recommendations (e.g. age and target group recommendations and guidelines)	Recommendations available
URL link to Immunisation Guidelines for the Czech Republic	http://www.szu.cz/uploads/Epidemiologie/Influenza_vaccinati_on_recommendations_Czech_Republic.pdf
National Action Plan (NAP) as requested by EC	Adopted
URL link to NAP	http://www.mzcr.cz/Verejne/dokumenty/narodni-akcni-plan_5329_1092_5.html

EUROSTAT links:

^aGDP per capita 2013 (accessed 15.12.2014): http://ec.europa.eu/eurostat/statistics-explained/index.php/GDP_per_capita,_consumption_per_capita_and_price_level_indices

^bHealth expenditures 2011(accessed 15.12.2014): http://ec.europa.eu/eurostat/statistics-explained/index.php/General_government_expenditure_on_social_protection_and_health

^cTotal population and those > 65 years of age 2011(accessed 15.12.2014): <https://ec.europa.eu/CensusHub2/intermediate.do?&method=forwardResult>

^dPopulation with chronic medical conditions 2006: http://www.ecdc.europa.eu/en/publications/Publications/0808_GUI_Priority_Risk_Groups_for_Influenza_Vaccinati_on.pdf (Fleming, D.M. and A.J. Elliot, Estimating the risk population in relation to influenza vaccination policy. 2006 May 15; 24(20):4378-85)

^e Number of live births in 2011(accessed 15.12.2014): <http://ec.europa.eu/eurostat/tgm/table.do?tab=table&init=1&language=en&pcode=tps00111&plugin=1>

Seasonal influenza vaccination recommendations and payment mechanism for vaccination

Vaccination recommendations (population groups targeted by vaccination)	
Overall population	No recommendation
Healthy children and adolescents	No recommendation
Older population groups: ≥65 years of age	Recommended
Chronic medical conditions	Recommended: <ul style="list-style-type: none"> - Pulmonary diseases; - Neurologic diseases; - Cardiovascular diseases; - Renal diseases; - Hepatic diseases; - Metabolic disorders; - Immunosuppressed individuals; - HIV/AIDS.
	No recommendation: <ul style="list-style-type: none"> - Haematological disorders; - Morbid obesity, - Long-term aspirin use (children <18 years).
Pregnancy-related vaccination (including post-partum women)	Recommended: <ul style="list-style-type: none"> - For all pregnant women at any stage during pregnancy.
	No recommendation: <ul style="list-style-type: none"> - Postpartum women if not vaccinated during pregnancy.
Healthcare workers	Recommended: <ul style="list-style-type: none"> - To all healthcare workers
Other occupational groups	na
Population groups in closed communities	Recommended: <ul style="list-style-type: none"> - For residents of long- term care facilities;
	No recommendation: <ul style="list-style-type: none"> - For prisoners; - For children in day care centres
Household contacts or carer of:	Recommended: <ul style="list-style-type: none"> - Individuals with chronic medical conditions.
	No recommendation: <ul style="list-style-type: none"> - Infants <6 months of age; - Immunosuppressed individuals; - ≥65 years of age.

na: Not applicable

Payment mechanism for vaccine and its administration for the population groups targeted by seasonal influenza vaccine		
	For vaccine	For administration
Overall population	na	na
Healthy children and adolescents	na	na
Older population groups (≥ 65 years of age) ^a	National insurance scheme	National insurance scheme
Chronic medical conditions groups (by group) ^b	National insurance scheme; The list of chronic diseases to be reimbursed from insurance is shorter than the list of chronic diseases from national vaccine recommendation	National insurance scheme
Pregnancy-related vaccination (including post-partum women)	NA	NA
Health care workers (including staff of long-stay care facilities)	Out of pocket ^c ; Employer	Out of pocket ^c ; Employer
Other occupational groups	na	na
Population groups in closed communities ^{a,b}	National insurance scheme	National insurance scheme
Household contacts or care givers ^d	Out of pocket	Out of pocket

na: Not applicable

NA: Not available

^a Co-payment for vaccine exist. Only cheapest vaccine is covered from insurance for people ≥ 65 of age. For other vaccine(s), there is need to pay the difference.

^b Co-payment for vaccine exist. Only cheapest vaccine is covered from insurance for people with chronic conditions. For other vaccine(s), you have to pay the difference.

^c 100% paid by vaccine receiver or employer.

^d You have to pay 100%.

National insurance scheme: health contributions are paid to the insurance fund and then for this contribution there is a package of services received. It is not by default that you receive the services if you do not pay the insurance contributions.

National health service: taxes are paid by a citizen or resident of the country and this person is covered by the health service.

Out of pocket: not reimbursed, paid by receiver of vaccine.

Vaccination coverage rates

Vaccination coverage (%) in population groups targeted by seasonal influenza vaccination the from 2008–09 to the 2012–13 influenza season by method of data collection (administrative and /or survey)

Population group	Influenza season									
	2008–09		2009–10		2010–11		2011–12		2012–13	
	Admin.	Surv.	Admin.	Surv.	Admin.	Surv.	Admin.	Surv.	Admin.	Surv.
Overall population	7.2	na	7.8	na	NA	na	NA	na	NA	na
Children/adolescents	na	na	na	na	na	na	na	na	na	na
Older population groups: ≥65 years of age	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Chronic medical conditions groups	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Pregnant women ^a	-	-	-	-	NA	NA	NA	NA	NA	NA
Healthcare workers	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
Staff in long-stay care facilities ^b	-	-	-	-	-	-	NA	NA	NA	NA
Residents in long stay care facilities ^b	-	-	-	-	-	-	NA	NA	NA	NA

na: Not applicable

NA: Not available

^a VENICE started to collect vaccination coverage data for pregnant women after the A(H1N1)pdm09 (2010-11 influenza season).

^b VENICE started to collect vaccination coverage data for staff and residents in long-stay care facilities for the influenza season 2011-12.

Methods to monitor vaccination coverage, safety and effectiveness

Monitoring of vaccination coverage during the 2012–13 influenza season

Method used to monitor influenza vaccination coverage

Administrative method only

Method used (administrative, survey) to monitor vaccination coverage by population group

Administrative	Survey
Do not monitor vaccination coverage in any population groups recommended vaccine (e.g. ≥65 years of age; those with chronic medical conditions; pregnant women, healthcare workers).	na

na: Not applicable

Details on administrative method used (medical records vs. immunisation registry; manual vs. electronic) by population group

Medical records		Immunisation registry	
Manual	Electronic	Manual	Electronic
na	na	No	No

na: Not applicable

Numerator assessment		
Pharmaceutical data	Administrative data	Frequency of numerator assessment
Not used	Aggregate collection of number of vaccines administered	Once, at the end of the influenza season

Denominator assessment by population groups and data source	
Population group	Data source for population group
Entire population	Not used
Children and adolescents	Not used
Adults	Not used
Individuals with medical/risk conditions (clinical risk groups)	Not used
Pregnant women	Not used
Healthcare workers	Not used
Essential public sector workers	Not used
Prisoners	Not used
Residents of long-term care institutions	Not used
Educational institutions	Not used
Other, please specify	Used. Individuals with chronic medical conditions plus people of age ≥ 65 together; number of vaccine administered, one summary number from health insurance company

Details for survey method used for the 2012–13 influenza season			
Type of the survey	Survey mode	Sampling strategy	Sample size
na	na	na	na

na: Not applicable

Vaccine safety monitoring (adverse events following immunisation AEFV)				
Data collected at the national and at the regional level	Data linkage with immunisation registry	Details collected	Status of reporting	AEFV reported to
Yes	No	Yes, case based data including age, sex and suspected symptoms should be reported	Not mandatory	State Institute for Drug Control

Monitoring of influenza vaccine break-through ^a infections in vaccinated individuals		
Data collected at the national and at the regional level	Data linkage with immunisation registry	Details collected
There is no such system	na	na

na: Not applicable

^a Break-through infection is defined as laboratory-confirmed influenza infection >14 days after seasonal influenza vaccination in the current season (i.e. vaccine failure).

Vaccine procurement and delivery

Influenza vaccine procurement and delivery, 2012–13 influenza season		
Number of doses		
Purchased	Distributed	Used
NK	NK	NK

NK: Not known

Type of vaccine/Product Name	Target groups
Trivalent inactivated non-adjuvanted vaccines (TIV)	
Used	
Abbott; Sanofi Pasteur;	Children and adolescents; Healthy adults; Older adults (e.g. ≥60/65 years); Those with medical condition/s; Pregnant women; Residents of long stay care facilities; Health Care Workers; Other occupational groups
Trivalent inactivated adjuvanted vaccines (aTIV)	
Not used	
Trivalent live attenuated nasal vaccine (LAIV)	
Not used	
Quadrivalent attenuated nasal vaccine (LAIV)	
Not used	
Quadrivalent inactivated non-adjuvanted vaccine (QIV)	
Not used	

Promoting seasonal influenza vaccination

Promoting seasonal influenza vaccination during the 2012–13 influenza season	
Promotion activities with the general public and healthcare workers	Source of information (if yes)
General public	
No	na
Population over 65	
Yes	Leaflets; Posters; Other: press conference, discussion with experts
Pregnant women	
No	na
Chronic medical conditions	
Yes	Leaflets; Posters; Other: press conference, discussion with experts
Healthcare workers	
No	na

na: Not applicable

Use of antiviral agents for treatment and chemoprophylaxis of influenza

Recommendations and/or guidelines (policy document) on antiviral use	
Recommendations available	
Use of antiviral agents for treatment and chemoprophylaxis of influenza during the 2012–13 influenza season	
Use of antivirals for <u>treatment</u> for in-patients and out-patients who are at higher risk of developing influenza complications	
For in-patients who:	
<ul style="list-style-type: none"> - have severe, complicated influenza-like illness (ILI); - have progressive influenza-like illness; 	Recommended
<ul style="list-style-type: none"> - require hospitalisation due to influenza-like illness. 	No recommendation
For out-patients who are at higher risk of developing influenza complications on the basis of their age or underlying medical conditions:	
<ul style="list-style-type: none"> - Children <2 years; - Children <5 years; - Adults aged ≥65 years; - Individuals belonging to risk groups. - Women who are pregnant or postpartum (within 6 weeks after delivery); - Residents of nursing homes and other chronic-care facilities. 	No recommendation
Use of antivirals for <u>post-exposure</u> prophylaxis	
For family or other close contacts of a person at higher risk for influenza complications who have not been vaccinated with influenza vaccine at the time of exposure;	No recommendation
For unvaccinated healthcare workers with occupational exposure and who did not use personal protective equipment at the time of exposure	No recommendation
Use of antivirals for <u>pre-exposure</u> prophylaxis	
For individuals who are at high risk (e.g. severely immunosuppressed patients) for influenza-related complications who cannot otherwise be protected during times when a high risk for exposure exists	No recommendation
Use of antivirals for <u>control of influenza outbreaks</u>	
For individuals in long-term care facilities/care for immunocompromised individuals if not vaccinated or if the circulating influenza strain does not match the vaccine strains	No recommendation
For unvaccinated healthcare staff who provide care to individuals at high risk of developing complications in long-term care facilities/ care for immunocompromised patients if not vaccinated or if the circulating influenza strain does not match the vaccine strains	No recommendation
For all health care staff regardless of whether they received an influenza vaccination if the circulating influenza strain does not match the vaccine strains	No recommendation
Prisoners	No recommendation
Educational institutions	No recommendation
Existence of antiviral resistance surveillance system	
Antiviral resistance surveillance system	There is no antiviral resistance surveillance system in place

Country profiles are based on the [Seasonal Influenza Vaccination in Europe](#) report produced by the European Centre for Disease Prevention and Control (ECDC) and the Vaccine European New Integrated Collaboration Effort III (VENICE III). The data are from the seasonal influenza vaccination survey for 2012–13 season in EU/EEA countries. Results above use the same data as was available when the report was published. During the validation process in June 2015, minor changes were introduced in some country profiles. Therefore, data may be different to those available in the report.